| Literature DB >> 32049413 |
Alice Santoro1, Jenifer S Calvo2, Manuel David Peris-Díaz3, Artur Krężel3, Gabriele Meloni2, Peter Faller1.
Abstract
Copper complexes are of medicinal and biological interest, including as anticancer drugs designed to cleave intracellular biomolecules by O2 activation. To exhibit such activity, the copper complex must be redox active and resistant to dissociation. Metallothioneins (MTs) and glutathione (GSH) are abundant in the cytosol and nucleus. Because they are thiol-rich reducing molecules with high CuI affinity, they are potential competitors for a copper ion bound in a copper drug. Herein, we report the investigation of a panel of CuI /CuII complexes often used as drugs, with diverse coordination chemistries and redox potentials. We evaluated their catalytic activity in ascorbate oxidation based on redox cycling between CuI and CuII , as well as their resistance to dissociation or inactivation under cytosolically relevant concentrations of GSH and MT. O2 -activating CuI /CuII complexes for cytosolic/nuclear targets are generally not stable against the GSH/MT system, which creates a challenge for their future design.Entities:
Keywords: bioinorganic chemistry; copper-based drugs; glutathione; metallothionein; redox activity
Mesh:
Substances:
Year: 2020 PMID: 32049413 PMCID: PMC7294961 DOI: 10.1002/anie.201916316
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336